Latest Industry Insights

We recently spoke with Jed Coleman, co-founder of Curve.life, an online service aiming to provide cancer patients with evidence-based information about how they can empower themselves after diagnosis.

Recent developments in MS technology have enabled a fourth dimension of analysis: ion mobility separation. The term "4D proteomics" has been created to describe analysis that incorporates all four dimensions. We interviewed two researchers at the forefront of the proteomics field to learn more about how 4D proteomics approaches are enhancing their research.

10 things to note about viral vector manufacturing, regarding the complexities and challenges, and the technology that will help drive cell and gene therapy forward. Here we share insights from Pall and Molmed representatives, who are leaders in the fields of bioprocessing and cell and gene therapy.

We recently spoke with Paul Wotton, Ph.D., CEO at Obsidian Therapeutics, to gain his insights on the genetically engineered cell-therapy research area, and to learn how Obsidian Therapeutics' cytoDRiVE platform can increases the specificity and safety of such therapies.

We recently spoke with Luca Quagliata, Ph.D., Global Director of Medical Affairs for Thermo Fisher Scientific. Previously, Quagliata was involved in one of the first teams in Europe to introduce Next Generation Sequencing (NGS) in routine molecular diagnostics. Here, he shares his perspectives on the field, particularly the use of NGS in the analysis of liquid biopsies, the discovery of cancer biomarkers and the potential application of artificial intelligence (AI) in molecular diagnostics.

We recently spoke with Dr Marian Rehak, VP of Research and Development at Sphere Fluidics, to learn more about the importance of single cell analysis. Marian touches on some of the common challenges encountered and highlights some of the key applications.

Agilent Technologies Inc. recently announced it had signed an agreement to acquire BioTek Instruments, a global leader in life science instrumentation.

In this interview, Aaron Hudson, Vice President & General Manager, Global Marketing & Strategy at SCIEX, discusses why precision quantification, specifically quantitative mass spectrometry (MS), is the best approach for measuring the transition from "wellness" to illness.

We recently spoke with Eric Hobbs, CEO at Berkeley Lights to learn more about "digital cell biology". Eric also describes how optofluidics can be used to gain fast, comprehensive measurements and insights across thousands of cells in parallel.

By studying gene expression modifications induced by the immune response, Novigenix has developed a blood test for colorectal cancer. This Q&A with Jan Groen, CEO, provides insights on the test, and on the field of study that could revolutionize cancer diagnosis.